Key result
Gene therapy shows significant benefit for saphenous vein graft disease.
Why the study?
Up to 40% of saphenous vein grafts occlude within 10 years after coronary artery bypass grafting, and the mechanisms and pathology of this disease require detailed review.
This review highlights the mechanisms of saphenous vein graft disease and the potential future role of gene therapy in its management.
Answers are grounded in this paper and cite their sources.
Gene therapy signals in saphenous vein graft disease remain preliminary; leaves open the need for randomized confirmation before clinical consideration.
Coronary artery bypass grafting is an effective treatment for myocardial ischaemia and is particularly important in patients with multivessel disease and diabetes. However, up to 40% of saphenous vein grafts will occlude within 10 years of surgery. The predominant mechanisms for saphenous vein graft disease are thrombosis, intimal hyperplasia, and accelerated atherosclerosis. The pathology of these changes and the role of key factors such as nitric oxide, cellular proliferation, and the role of hypercholesterolemia and hypertriglyceridaemia, are reviewed. Saphenous vein graft disease is among the first cardiovascular conditions to show significant benefit from gene therapy and promises to show remarkable developments in the near future.
No takes yet. Share an insight, caveat, or question.
Lau et al. (2004) conducted a review in Cardiac Saphenous Vein Bypass Graft Disease. Saphenous vein graft disease, driven by thrombosis, intimal hyperplasia, and atherosclerosis, is among the first cardiovascular conditions to show significant benefit from gene therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: